Piper Sandler Maintains Overweight on CymaBay Therapeutics, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on CymaBay Therapeutics (NASDAQ:CBAY) and raises the price target from $19 to $33.
November 06, 2023 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has maintained an Overweight rating on CymaBay Therapeutics and raised the price target from $19 to $33.
The news is directly related to CymaBay Therapeutics. Piper Sandler's decision to maintain an Overweight rating and raise the price target indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100